BR9708540B1 - formulações injetáveis de avermectinas ou milbemicinas à base de óleo de mamona. - Google Patents

formulações injetáveis de avermectinas ou milbemicinas à base de óleo de mamona.

Info

Publication number
BR9708540B1
BR9708540B1 BRPI9708540-5A BR9708540A BR9708540B1 BR 9708540 B1 BR9708540 B1 BR 9708540B1 BR 9708540 A BR9708540 A BR 9708540A BR 9708540 B1 BR9708540 B1 BR 9708540B1
Authority
BR
Brazil
Prior art keywords
avermectins
castor oil
milbemycin
injectable formulations
pct
Prior art date
Application number
BRPI9708540-5A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9708540A (pt
Inventor
Michael Dr Grosse-Bley
Richard Dr Kujanek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7790774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9708540(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR9708540A publication Critical patent/BR9708540A/pt
Publication of BR9708540B1 publication Critical patent/BR9708540B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI9708540-5A 1996-04-09 1997-03-27 formulações injetáveis de avermectinas ou milbemicinas à base de óleo de mamona. BR9708540B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19613972A DE19613972A1 (de) 1996-04-09 1996-04-09 Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
PCT/EP1997/001569 WO1997037653A1 (de) 1996-04-09 1997-03-27 Injektionsformulierungen von avermectinen und milbemycinen auf basis von rizinusöl

Publications (2)

Publication Number Publication Date
BR9708540A BR9708540A (pt) 1999-08-03
BR9708540B1 true BR9708540B1 (pt) 2010-07-27

Family

ID=7790774

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9708540-5A BR9708540B1 (pt) 1996-04-09 1997-03-27 formulações injetáveis de avermectinas ou milbemicinas à base de óleo de mamona.

Country Status (13)

Country Link
US (1) US6063394A (OSRAM)
EP (1) EP0896534B1 (OSRAM)
JP (1) JP4257870B2 (OSRAM)
CN (1) CN1095662C (OSRAM)
AT (1) ATE285233T1 (OSRAM)
AU (1) AU718807B2 (OSRAM)
BR (1) BR9708540B1 (OSRAM)
CA (1) CA2251087C (OSRAM)
DE (2) DE19613972A1 (OSRAM)
ES (1) ES2235230T3 (OSRAM)
NZ (1) NZ332224A (OSRAM)
PT (1) PT896534E (OSRAM)
WO (1) WO1997037653A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19638045A1 (de) * 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
KR100499438B1 (ko) * 1997-12-03 2005-07-07 머크 앤드 캄파니 인코포레이티드 수소화 피마자유를 함유하는 지속성 주사제
US6174540B1 (en) 1998-09-14 2001-01-16 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated caster oil
GB9827727D0 (en) * 1998-12-16 1999-02-10 Pfizer Ltd Antiparasitic formulations
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
AU781682B2 (en) * 2000-03-20 2005-06-09 Zoetis Services Llc Sustained-release compositions for parenteral administration
US20050009762A1 (en) * 2003-06-06 2005-01-13 Strobel Michael Albert Application of water and organic solvent soluble ivermectin for topical and oral use
CN1275589C (zh) * 2002-05-31 2006-09-20 王玉万 含抗寄生虫药物的缓释注射剂
US7262214B2 (en) 2003-02-26 2007-08-28 Merial Limited 1-N-arylpyrazole derivatives in prevention of arthropod-borne and mosquito-borne diseases
US20050271459A1 (en) * 2004-06-03 2005-12-08 World Wide Stationery Mfg. Co., Ltd. Interlocking ring tip formations for paired ring members of a ring binder mechanism
NZ534939A (en) * 2004-08-26 2007-04-27 Bomac Research Ltd Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility
DE102004053964A1 (de) * 2004-11-09 2006-05-11 Bayer Healthcare Ag Mittel gegen Demodikose
TW200922635A (en) * 2007-08-31 2009-06-01 Archimedes Dev Ltd Non-aqueous pharmaceutical compositions
NZ590141A (en) * 2008-06-24 2012-05-25 Merial Ltd Anthelminthic formulations including castor oil and another vegetable oil
ES2399228T3 (es) 2009-02-16 2013-03-26 Ah Usa 42 Llc Formulación de doramectina a dosis elevada
CN101773467B (zh) * 2010-01-20 2015-09-09 北京大北农动物保健科技有限责任公司 一种美贝霉素或美贝霉素肟的兽用缓释注射液及制备方法
KR101805087B1 (ko) * 2010-09-16 2017-12-05 주식회사 엘지화학 높은 방부력을 제공하는 오일 주사 제형
CA2867079A1 (en) * 2012-03-13 2013-09-19 Bayer New Zealand Limited Long acting compositions
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
CN119157876A (zh) 2017-12-15 2024-12-20 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
PY2013845A (es) * 2019-03-01 2021-02-09 Boehringer Ingelheim Animal Health Usa Inc Composiciones inyectables de clorsulón, sus métodos y usos
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
US11077134B1 (en) 2020-11-10 2021-08-03 Mountain Valley Md Inc Water dissolvable macrocyclic lactone cyclodextrin complexes
US11638714B2 (en) 2020-11-10 2023-05-02 Mountain Valley Md Inc Water dissolvable macrocyclic lactone cyclodextrin complexes
US11918572B2 (en) * 2022-01-28 2024-03-05 Rebel Medicine Inc Pharmaceutical compositions for treating pain
CN114642632A (zh) * 2022-02-25 2022-06-21 河北科技大学 一种莫西克汀注射液及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4914624A (OSRAM) * 1972-06-08 1974-02-08
SE434277B (sv) * 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4199569A (en) * 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
OA06863A (fr) * 1980-08-04 1983-02-28 Merck & Co Inc Solubilisation de l'invermectine dans l'eau.
NZ210505A (en) * 1983-12-22 1988-06-30 Merck & Co Inc Parasiticidal compositions containing avermectin or milbemycin derivatives
DE3727648A1 (de) * 1987-08-19 1989-03-02 Bayer Ag Neue avermectin derivate, verfahren zu ihrer herstellung und ihre verwendung
US5510117A (en) * 1989-03-09 1996-04-23 Micro-Pak, Inc. Entrapment vehicle and method
DK0393890T3 (da) * 1989-04-11 1992-09-28 Pfizer Injicerbart præparat indeholdende 25-cyclohexyl-avermectin B1
NZ234802A (en) * 1989-08-14 1992-11-25 Merck & Co Inc Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals
DE69208765T2 (de) * 1991-07-23 1996-09-26 American Cyanamid Co Stabile Zusammensetzungen für parenterale Verabrechung und ihre Verwendung
ATE180671T1 (de) * 1991-09-30 1999-06-15 Merck & Co Inc Hydrierte rizinusöl-enthaltende injizierbare formulierungen mit verlängerter wirkstoffabgabe
WO1994008566A1 (en) * 1992-10-21 1994-04-28 Micro Vesicular Systems, Inc. Entrapment vehicle and method

Also Published As

Publication number Publication date
PT896534E (pt) 2005-04-29
NZ332224A (en) 2000-06-23
AU718807B2 (en) 2000-04-20
CA2251087C (en) 2008-01-15
US6063394A (en) 2000-05-16
AU2506697A (en) 1997-10-29
HK1019404A1 (en) 2000-02-11
EP0896534A1 (de) 1999-02-17
ATE285233T1 (de) 2005-01-15
ES2235230T3 (es) 2005-07-01
CN1095662C (zh) 2002-12-11
CN1215331A (zh) 1999-04-28
EP0896534B1 (de) 2004-12-22
JP4257870B2 (ja) 2009-04-22
DE59712134D1 (de) 2005-01-27
WO1997037653A1 (de) 1997-10-16
DE19613972A1 (de) 1997-10-16
BR9708540A (pt) 1999-08-03
CA2251087A1 (en) 1997-10-16
JP2000508301A (ja) 2000-07-04

Similar Documents

Publication Publication Date Title
BR9708540A (pt) Formulações injetáveis de avermectinas e milbemicinas baseadas em óleo de mamona
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
YU15299A (sh) Farmaceutski sastavi
NO2005009I2 (no) Emselex-darifenacin. Iupac-navn: (S)-2-ä1-Ä2-(2,3 -dihydrobenzofuran-5-yl)etylÜ-3-pyrrolidinylü-2,2-difenylacetamid
ATE283067T1 (de) Detoxifizierte mutanten bakterieller adp- ribosylierender toxine als parenterale adjuvantien
IL137093A0 (en) Methods of inactivating bacteria including bacterial spores
FI990596L (fi) Luun morfogeneettiset proteiini-16 (BMP-16) -koostumukset
NO20002830L (no) Langtidsvirkende, injiserbare formuleringer inneholdende hydrogenert lakserolje
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
ATE228845T1 (de) Injektionsformulierungen von avermectinen und milbemycinen
IT1293910B1 (it) Bracciolo di sedia, e sedia utilizzante tale bracciolo.
PT1119359E (pt) Formulacao de 2-metil-tieno-benzodiazepina
EP1834670A3 (en) Anthelmintic compositions containing combinations of avermectins or milbemycins with bis-aryl compounds
ES2162929T3 (es) Procedimiento para la preparacion de 2-(1-azabiciclo(2.2.2)oct-3-il)-2,4,5,6-tetrahidro-1h-benz(de)isoquinolin-1-ona y producto intermediario.
ATE251457T1 (de) Substituierte 1,2,3,4-tetrahydro-2- dibenzofuranamine und 2- aminocyclohepta(b)benzofurane
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
ES2175356T3 (es) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4 fluorofenil)et il[-4- piperidinmetanol en el tratamiento de trastornos depresivos y trastornos bipolares.
ATE215084T1 (de) Imidazopyridin-azolidinone
PT938306E (pt) Composicoes antimalaricas contendo derivados de ciclopenteno-1,2,4-trioxano fundidos em cis
EP0841057A3 (de) Phospholipidische Zusammensetzung, Verfahren zur Herstellung einer derartigen Zusammensetzung und Verwendung derselben
DK0823505T3 (da) Fremgangsmåde til trichromi-farvning eller -trykning
ES2165020T3 (es) Monohidrato de famciclovir.
NZ330913A (en) Antigens for preventing and reducing parasite infection and disease
Barrett Relocation of the office of the Journal of Hospital Infection

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE PATENTE COM BASE NOS ARTIGOS 8, 11 E 13 DA LPI NO 9.279 DE 14/05/1996

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAYER ANIMAL HEALTH GMBH (DE)

Free format text: TRANSFERIDO DE: BAYER AKTIENGESELLSCHAFT

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/07/2010, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061190/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132255-93.2013.4.02.51011 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: BAYER AKTIENGESELLSCHAFT, BAYER ANIMAL HEALTH GMBH, BAYER CROPSCIENCE AG.

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)